Search
Daunorubicin reduces cardiomyopathy risk compared with doxorubicin in childhood cancer survivors
- OPACC
- Jan 31, 2019
- 1 min read
Daunorubicin appeared associated with a lower cardiomyopathy risk than doxorubicin among childhood cancer survivors, according to a multicenter cohort study published in JAMA Oncology.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
Comments